Although activation of the PD-1/PD-L1 axis is associated with poorer outcomes in advanced cancer stages, high PD-L1 expression also renders tumor cells more sensitive to PD-1/PD-L1 inhibitors. This evidence concerns the gene CD274 and cancer.